6 Spam-Free Article(s) Found
Oct 22, 2019 - Sarepta Therapeutics' (SRPT) third-quarter results are expected to reflect the impact of strong demand for Exondys 51. Regulatory update related to golodirsen is what investors are expected be focused on.
Oct 21, 2019 - AstraZeneca's (AZN) third-quarter result is expected to reflect the impact of new drug sales.
Oct 18, 2019 - Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Oct 17, 2019 - Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.
Oct 16, 2019 - Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.
Oct 16, 2019 - Novavax (NVAX) starts a pivotal late-stage study on its pipeline candidate NanoFlu influenza vaccine in senior patients. Shares up.